Register

AI x Biology Workshop
2025

Organized by
Lighthaven
Berkeley, CA
May 9 – 10
2025
Apply now
A 2-day cross-disciplinary workshop

Gathering minds from artificial intelligence and biology to accelerate the future of medicine.

Why attend?

Unlock New Insights

Learn from pioneers using AI to explore new frontiers in biology and health

Bridge the AI-Bio Gap

Connect with experts across both fields to tackle shared challenges and opportunities

Turn Ideas into Action

Focus on concrete next steps for accelerating research and therapeutic development

Contribute to a Field-Defining Paper

Workshop insights will be synthesized into a paper to inspire large-scale, transformative initiatives.

Speakers

Mariëlle van Kooten
Postdoctoral Research Scholar, Stanford University

Mariëlle is a scientist, engineer and entrepreneur who aims to develop transformative technology that will accelerate progress in the longevity community, move the frontiers of synthetic biology, and shape commercial initiatives that target mitochondrial disease and dysfunction. As a Postdoctoral Research Fellow at Stanford University, Mariëlle set out to deduce and employ gene regulatory networks in human cells at RNA isoform resolution to improve human health.

Mariëlle van Kooten
Postdoctoral Research Scholar, Stanford University
Zihao Ou
Assistant Professor, The University of Texas at Dallas

Dr. Zihao Ou is an Assistant Professor in the Biomedical Science Program and the Department of Physics at the University of Texas at Dallas. Dr. Ou’s research focus lies at the intersection of fundamental physical principles and cutting-edge genetic and molecular advancements. His goal is to create advanced imaging platforms that allow real-time monitoring of materials and biological processes in their native environments.

Zihao Ou
Assistant Professor, The University of Texas at Dallas
Sam Rodriques
Director and CEO, FutureHouse

Dr. Sam Rodriques is a physicist, bioengineer, and entrepreneur with extensive experience in academic research and biotechnology innovation. He is the founder and CEO of FutureHouse, a research lab in San Francisco dedicated to developing an AI Scientist to accelerate scientific discovery. Before establishing FutureHouse in 2023, Dr. Rodriques led the Applied Biotechnology Laboratory at the Francis Crick Institute, where he focused on integrating bioengineering and business to advance medical and biological research. His notable inventions include technologies for spatial and temporal transcriptomics, brain mapping, gene therapy, and nanofabrication. Throughout his career, Dr. Rodriques has been committed to accelerating scientific research through innovative technologies and interdisciplinary approaches. His work aims to revolutionize the pace of discovery and provide global access to cutting-edge scientific, medical, and engineering expertise.

Relevant Content
No items found.
Sam Rodriques
Director and CEO, FutureHouse
Morgan Levine
Vice President of Computation, Altos Labs

Dr. Morgan Levine is a prominent scientist specializing in the biology of aging, with extensive experience in academic research and computational biology. She currently serves as the Vice President of Computation at Altos Labs, a biotechnology company focused on restoring cell health and resilience through cell rejuvenation. Dr. Levine's scientific background encompasses bioinformatics, cellular biology, complex systems, and biostatistics. She is renowned for developing innovative methods to quantify the molecular and physiological changes that occur over an organism's lifetime, integrating interdisciplinary approaches to track the trajectories of aging cells and organisms. Her vision includes creating multi-scale computational models to elucidate how dynamic molecular states of cells lead to health and disease manifestations at various biological levels. Her work aims to uncover the principles of aging and develop interventions to promote healthy longevity.

Morgan Levine
Vice President of Computation, Altos Labs
Alexandru Băcița
Co-Founder and COO, The Cat Health Company

Alexandru Băcița is a scientist and entrepreneur with extensive experience in drug discovery and development. He is the co-founder and Chief Operating Officer of The Cat Health Company (TCHC), a biotech startup dedicated to extending feline longevity through innovative therapies. Before co-founding TCHC, Alexandru served as a Senior Scientist at Charles River Laboratories, a leading provider of services for drug discovery and clinical trials. At TCHC, Alexandru focuses on developing computational pipelines to predict new therapies for rare diseases and age-related conditions in cats. His work aims to enhance feline health and longevity, providing pets with longer, healthier lives

Alexandru Băcița
Co-Founder and COO, The Cat Health Company
Alex Voda
Co-founder & CEO, The Cat Health Company

Alexandrul-Ioan Voda, DPhil, is a passionate leader in regenerative medicine, bioinformatics, and biotech. As CEO of The Cat Health Company, Alex leverages a diverse skill set combining wet-lab and computational sciences to drive advancements in biomedical research. A coding aficionado fluent in Python, R, and Bash, Alex specializes in machine learning, data structures, and algorithms. With a DPhil from the University of Oxford, he has contributed to groundbreaking work in inflammatory bowel disease genetics, aging clocks, and human health. His experience spans both academic and industry sectors, with a strong focus on innovation and scientific leadership.

Alex Voda
Co-founder & CEO, The Cat Health Company
John Cumbers
Founder & CEO, SynBioBeta

John Cumbers is a British molecular biologist and entrepreneur based in the San Francisco Bay Area. He is the founder and CEO of SynBioBeta, an organization that promotes synthetic biology to build a more sustainable universe. John also founded BetaSpace, a space settlement innovation network, and is an operating partner at DCVC, a venture capital firm focused on biotechnology investments. His work at NASA and his contributions to synthetic biology have earned him multiple awards and recognition in the field.

John Cumbers
Founder & CEO, SynBioBeta
Derya Unutmaz
Professor, The Jackson Laboratory

Derya Unutmaz, MD, is a distinguished professor at The Jackson Laboratory, renowned for his pioneering work on human T cell differentiation, activation, and regulation in immunity, diseases, and aging. With a medical degree from Marmara University, Istanbul, he also holds a concurrent professorship at the University of Connecticut Health Center. Dr. Unutmaz’s research has transformed understanding of T cell dysfunction in diseases like HIV and chronic fatigue syndrome. His work aims to optimize immune responses and develop therapies that combat age-related diseases, advancing healthier aging and immune system treatments.

Derya Unutmaz
Professor, The Jackson Laboratory
Alfredo Andere
Co–founder & CEO, Latch Bio

Alfredo Andere is the co-founder and CEO of LatchBio, a platform that provides biology companies with the tools to store, transform, and analyze large data sets. Before founding LatchBio, he worked as a Data Engineer at Facebook and a Software Engineer at Google Brain, gaining valuable experience in handling large-scale data. Alfredo and his co-founders envisioned bringing high-quality computational infrastructure to the field of biology, and they dropped out of their senior year at UC Berkeley to pursue this goal. Since its inception, LatchBio has raised significant funding and serves numerous biotech companies.

Alfredo Andere
Co–founder & CEO, Latch Bio
Daniel Ives
Founder & CEO, Shift Bioscience

Daniel Ives is the CEO and founder of Shift Bioscience, a company dedicated to reversing cellular aging using AI-guided cellular rejuvenation techniques. With a background in mitochondrial biology from the University of Cambridge, Daniel has been at the forefront of developing innovative solutions to combat age-related diseases. His work focuses on leveraging advanced machine learning and epigenetic aging clocks to discover new therapeutic interventions that can extend human healthspan.

Daniel Ives
Founder & CEO, Shift Bioscience
Allison Duettmann
CEO & President, Foresight Institute

Allison Duettmann is the President and CEO of the Foresight Institute, where she directs programs on Intelligent Cooperation, Molecular Machines, Biotech & Health Extension, Neurotech, and Space Programs. She is also the Founder of Existential Hope and has co-edited works on superintelligence and co-authored books on future technologies. Allison holds an MS in Philosophy & Public Policy from the London School of Economics, focusing on AI Safety. She is a prominent advocate for leveraging technology to create a positive long-term future for humanity.

Allison Duettmann
CEO & President, Foresight Institute
Joe Betts-Lacroix
Founder & CEO, Retro Biosciences

Joe Betts-LaCroix is an American scientist and entrepreneur known for his discoveries in biophysics and for creating the world's smallest personal computer. He is currently the co-founder and CEO of Retro Biosciences, a company focused on developing therapeutics to increase healthy human lifespan by ten years. Joe has a background in earth sciences, biophysics, and computer hardware, and has contributed to significant advancements in both scientific research and technology innovation.

Joe Betts-Lacroix
Founder & CEO, Retro Biosciences
+ more to be announced
Guarantee your spot at AI x Bio @Vitalist Bay. Limited spots.
May 9 – 10. 2025.
Apply

About

Join us for an intensive workshop exploring how artificial intelligence might advance the life sciences and accelerate the development of therapies to extend healthy human lifespan.
Recent breakthroughs in AI, particularly in areas like protein structure prediction and drug discovery, have created unprecedented opportunities to tackle aging-related diseases and biological decline. This workshop brings together experts in machine learning, biology, and longevity research to explore practical applications of AI in extending human lifespan.

Focus Areas

Simulation & modelling

AI-powered simulations are bringing us closer to virtual models of cells, tissues, and even entire organisms.

Foundation models like ScGPT for single-cell gene expression, along with CZI’s cell atlas initiative, are paving the way for more accurate cellular simulations and new breakthroughs in drug discovery.

Large-scale data generation

What high-impact data generation efforts (spanning longitudinal studies and high-throughput experiments) can provide the essential training ground for next-gen AI x Bio models?

The Protein Data Bank (PDB) and AlphaFold’s predicted structure database demonstrate how massive, well-structured datasets can supercharge AI’s ability to model biological systems and discover new therapeutics.

Multi-omics & biomarkers

Applying advanced AI techniques to analyze and derive insights from complex biological datasets spanning genomics, proteomics, and metabolomics.

Companies like Tempus and Nference are using multi-omics analysis to uncover biomarkers for cancer and neurodegenerative diseases.

Drug discovery & development

Harnessing machine learning to identify novel therapeutics and repurpose existing drugs more efficiently.

A new wave of techbio startups apply generative AI and machine learning to protein engineering, target discovery, and insilico screening to develop new medicines.

Intelligent lab automation  

AI is revolutionizing laboratory research through robotic automation, streamlined workflows, and machine learning-guided experimentation.

How can new breakthroughs in AI + robotics / automation enable intelligent life science research at scale?

Why now?

The convergence of several factors makes this an optimal time to apply AI to biology

01.

Emerging computational power and AI capabilities, particularly in analyzing complex biological systems

02.

Growing datasets in aging research, including longitudinal studies and multi-omics data

03.

Maturing understanding of fundamental aging mechanisms that can be targeted therapeutically

04.

Increasing investment in both AI and longevity research, creating opportunities for cross-pollination

Join us

Join us to learn practical approaches for applying cutting-edge AI techniques to one of humanity’s greatest challenges. Suitable for researchers, data scientists, and professionals interested in the intersection of AI and longevity science.

Apply

Venue

Lighthaven Campus, Berkeley California. A beautifully designed environment for discussion, collaboration, and learning.

Address: 2740 Telegraph Avenue, Berkeley, CA.

Vitalist
Bay
Vitalist
Bay
Bay
Vitalist
Bay
Vitalist